Male And Female Scientists Working In Laboratory

Partnering for Novel Drug Discovery and Development

GigaGen collaborates with leading academic and biopharmaceutical researchers interested in using natural antibodies and T cell receptors (TCRs) to advance drug discovery and development programs. Our main areas of collaboration are:


  • Massively polyclonal natural repertoire antibodies

  • Cancer repertoire TCR discovery and development

  • Augmented mouse antibody discovery


Please contact us for more information.

Our current partners include:

Stanford logo

Located between San Francisco and San Jose in the heart of Silicon Valley, Stanford University is recognized as one of the world's leading research and teaching institutions. GigaGen is collaborating with Stanford on clinical immune monitoring and translational immunology research.

UCSF logo

The leading university exclusively focused on health, UC San Francisco is driven by the idea that when the best research, the best education and the best patient care converge, great breakthroughs are achieved. GigaGen is working with UCSF to research antibody based targets against significant disease.

Novartis logo

Novartis (NYSE: NVS) is a world leader that provides healthcare solutions that address the evolving needs of patients and societies. Novartis provides medicines and treatments to help patients and improve patient care. Gigagen is working with Novartis to discover a novel drug candidate.

home_logo

The COI approach is based on Avalon Ventures’ proven portfolio strategy for launching disruptive drug discovery, technology platform and healthcare IT companies in new market areas and providing ongoing support as they grow and increase in value. GigaGen is collaborating with COI to discover new autoimmune therapies.

bulletbio

Bullet Bio's BB-001 product trains the immune system to target a unique marker present on all B cells, the idiotype protein (commonly known as “Id”). By triggering an immune response directed towards the particular Id that is on an individual patient’s cancerous B cells, the patient’s immune system can eliminate these cells as threats.